Clinical Trials Logo

Portal Vein Thrombosis clinical trials

View clinical trials related to Portal Vein Thrombosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04055389 Withdrawn - Cirrhosis, Liver Clinical Trials

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

PiVoT
Start date: January 1, 2021
Phase: Phase 1
Study type: Interventional

To prevent portal vein thrombosis (PVT) in patients with cirrhosis at risk for PVT by pharmacologic prophylaxis with intravenous antithrombin (AT-III).

NCT ID: NCT02526303 Withdrawn - Liver Cirrhosis Clinical Trials

Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of anticoagulation in the treatment of non-occlusive portal vein thrombosis in patients with liver cirrhosis.

NCT ID: NCT01631877 Withdrawn - Clinical trials for Portal Vein Thrombosis

Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver

Start date: June 2012
Phase: N/A
Study type: Interventional

After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. The baseline Doppler parameter will be recorded and the patient will be randomized into either interventional (acenocoumarol) or placebo group along with first five days of subcutaneous Low Molecular Weight Heparin inj. Enoxaparin in the interventional arm and placebo injection in the control arm. Every 3 monthly the Doppler screening for recanalization of portal vein thrombus will be done with monitoring of International Normalized Ratio (INR)with target INR 2-3. Both the groups will receive the therapy for one year irrespective of the Doppler findings in relation to portal vein thrombus re-canalization.Then one year drug free monitoring will be done in both the groups as per the primary or secondary outcome. .